ITEM
1. FINANCIAL STATEMENTS
RITTER
PHARMACEUTICALS, INC.
CONDENSED
BALANCE SHEETS
|
|
March
31, 2017
|
|
|
December
31, 2016
|
|
|
|
(unaudited)
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
5,092,309
|
|
|
$
|
7,046,282
|
|
Prepaid
expenses
|
|
|
149,727
|
|
|
|
156,752
|
|
Total current assets
|
|
|
5,242,036
|
|
|
|
7,203,034
|
|
|
|
|
|
|
|
|
|
|
Other assets
|
|
|
10,326
|
|
|
|
10,326
|
|
Property and
equipment, net
|
|
|
22,235
|
|
|
|
23,542
|
|
Total
Assets
|
|
$
|
5,274,597
|
|
|
$
|
7,236,902
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’
EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
1,634,698
|
|
|
$
|
1,896,368
|
|
Accrued expenses
|
|
|
900,762
|
|
|
|
1,222,735
|
|
Other
liabilities
|
|
|
15,133
|
|
|
|
14,736
|
|
Total current liabilities
|
|
|
2,550,593
|
|
|
|
3,133,839
|
|
|
|
|
|
|
|
|
|
|
Stockholders’
equity
|
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value;
5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2017 and December 31, 2016
|
|
|
—
|
|
|
|
—
|
|
Common stock, $0.001 par value; 25,000,000 shares authorized;
11,619,197 shares issued and outstanding as of March 31, 2017 and December 31, 2016
|
|
|
11,619
|
|
|
|
11,619
|
|
Additional paid-in capital
|
|
|
49,853,196
|
|
|
|
49,559,020
|
|
Accumulated deficit
|
|
|
(47,140,811
|
)
|
|
|
(45,467,576
|
)
|
Total
stockholders’ equity
|
|
|
2,724,004
|
|
|
|
4,103,063
|
|
|
|
|
|
|
|
|
|
|
Total
Liabilities and Stockholders’ Equity
|
|
$
|
5,274,597
|
|
|
$
|
7,236,902
|
|
The
accompanying notes are an integral part of these financial statements.
RITTER
PHARMACEUTICALS, INC.
CONDENSED
STATEMENTS OF OPERATIONS
(Unaudited)
|
|
For
the Three Months Ended March 31,
|
|
|
|
2017
|
|
|
2016
|
|
Operating
costs and expenses
|
|
|
|
|
|
|
|
|
Research
and development
|
|
$
|
432,154
|
|
|
$
|
1,882,848
|
|
Patent
costs
|
|
|
77,702
|
|
|
|
32,364
|
|
General
and administrative
|
|
|
1,171,325
|
|
|
|
1,235,018
|
|
Total
operating costs and expenses
|
|
|
1,681,181
|
|
|
|
3,150,230
|
|
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
|
(1,681,181
|
)
|
|
|
(3,150,230
|
)
|
|
|
|
|
|
|
|
|
|
Other
income
|
|
|
|
|
|
|
|
|
Interest
income
|
|
|
7,946
|
|
|
|
20,566
|
|
Other
income
|
|
|
—
|
|
|
|
1,214
|
|
Total
other income
|
|
|
7,946
|
|
|
|
21,780
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(1,673,235
|
)
|
|
$
|
(3,128,450
|
)
|
|
|
|
|
|
|
|
|
|
Net
loss per share, basic and diluted
|
|
$
|
(0.14
|
)
|
|
$
|
(0.36
|
)
|
|
|
|
|
|
|
|
|
|
Weighted
average shares outstanding, basic and diluted
|
|
|
11,619,197
|
|
|
|
8,583,259
|
|
The
accompanying notes are an integral part of these financial statements.
RITTER
PHARMACEUTICALS, INC.
CONDENSED
STATEMENTS OF CASH FLOWS
(Unaudited)
|
|
For
the Three Months Ended March 31,
|
|
|
|
2017
|
|
|
2016
|
|
Cash flows from operating
activities
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(1,673,235
|
)
|
|
$
|
(3,128,450
|
)
|
Adjustments to reconcile net loss to
net cash used in operating activities:
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
1,307
|
|
|
|
1,254
|
|
Stock-based compensation
|
|
|
294,176
|
|
|
|
377,597
|
|
Changes in operating
assets and liabilities:
|
|
|
|
|
|
|
|
|
Prepaid expenses
|
|
|
7,025
|
|
|
|
45,131
|
|
Accounts payable
|
|
|
(261,670
|
)
|
|
|
1,388,708
|
|
Accrued expenses
|
|
|
(321,973
|
)
|
|
|
(409,963
|
)
|
Other
liabilities
|
|
|
397
|
|
|
|
—
|
|
Net
cash used in operating activities
|
|
|
(1,953,973
|
)
|
|
|
(1,725,723
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from investing
activities
|
|
|
|
|
|
|
|
|
Purchases
of property and equipment
|
|
|
—
|
|
|
|
(7,432
|
)
|
Net
cash used in investing activities
|
|
|
—
|
|
|
|
(7,432
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from financing
activities
|
|
|
|
|
|
|
|
|
Proceeds
from exercise of options on common stock
|
|
|
—
|
|
|
|
2,130
|
|
|
|
|
—
|
|
|
|
2,130
|
|
|
|
|
|
|
|
|
|
|
Net
decrease in cash and cash equivalents
|
|
|
(1,953,973
|
)
|
|
|
(1,731,025
|
)
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents at beginning of period
|
|
|
7,046,282
|
|
|
|
15,819,566
|
|
Cash
and cash equivalents at end of period
|
|
$
|
5,092,309
|
|
|
$
|
14,088,541
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure
of cash flow information
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
—
|
|
|
$
|
—
|
|
Cash paid for taxes
|
|
$
|
—
|
|
|
$
|
—
|
|
The
accompanying notes are an integral part of these financial statements.
RITTER
PHARMACEUTICALS, INC.
NOTES
TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
NOTE
1 — ORGANIZATION AND PRINCIPAL ACTIVITIES
Ritter
Pharmaceuticals, Inc. (“Ritter” or the “Company”) is a Delaware corporation headquartered in Los Angeles,
California. The Company was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural Sciences,
LLC, and converted into a Delaware corporation on September 16, 2008.
Ritter
Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases.
The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality
of prebiotic-based therapeutics. The Company’s lead compound, RP-G28, is currently under development for the treatment of
lactose intolerance. There currently is no drug approved by the Food and Drug Administration (“FDA”) for the treatment
of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide.
The
Company currently operates in one business segment focusing on the development and commercialization of RP-G28. The Company is
not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision
maker, the Chief Executive Officer. The Company does not currently operate any separate lines of business or separate business
entities.
NOTE
2 — BASIS OF PRESENTATION
The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s
financial position for the periods presented.
The
accompanying interim period unaudited condensed financial statements have also been prepared in accordance with GAAP and applicable
rules and regulations of the SEC regarding interim financial reporting. The condensed balance sheet as of March 31, 2017, the
condensed statements of operations for the three months ended March 31, 2017 and 2016, and the condensed statements of cash flows
for the three months ended March 31, 2017 and 2016, are unaudited, but include all adjustments, consisting only of normal recurring
adjustments, which the Company considers necessary for a fair presentation of its financial position, operating results and cash
flows for the periods presented. The condensed balance sheet at December 31, 2016 has been derived from audited financial statements
included in the Annual Report on Form 10-K filed with the SEC on February 27, 2017. The results for the three months ended March
31, 2017 are not necessarily indicative of the results expected for the full fiscal year or any other period.
The
accompanying interim period unaudited condensed financial statements and related financial information included in this Quarterly
Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2016.
RITTER
PHARMACEUTICALS, INC.
NOTES
TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
Going
Concern and Liquidity
The
accompanying condensed financial statements have been prepared assuming the Company will continue as a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has
not generated any product revenue and has not achieved profitable operations. For the three months ended March 31, 2017, the Company
had a net loss of approximately $1.7 million and had net cash used in operating activities of approximately $2.0 million. At March
31, 2017, the Company had working capital of approximately $2.7 million, an accumulated deficit of approximately $47.1 million,
and cash and cash equivalents of approximately $5.1 million. There is no assurance that profitable operations will ever be achieved,
and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and pre-clinical testing,
and commercialization of the Company’s products will require significant financing. These matters, among others, raise substantial
doubt about the Company’s ability to continue as a going concern.
Since
inception, the operations of the Company have been funded through the sale of common shares, preferred shares and convertible
debt. Management cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that
the Company raises additional funds by issuing equity securities, the Company’s stockholders may experience significant
dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct
business. If the Company is not able to raise additional capital when required or on acceptable terms, the Company may have to
(i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates;
(ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less
favorable than might otherwise be available; and/or (iii) relinquish or otherwise dispose of rights to technologies, product candidates
or products that the Company would otherwise seek to develop or commercialize.
The
financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
NOTE
3 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
There
have been no material changes in the Company’s significant accounting policies as of and for the three months ended March
31, 2017, as compared with the significant accounting policies described in the Company’s Annual Report on Form 10-K for
the fiscal year ended December 31, 2016.
Use
of Estimates
The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those
estimates.
Cash
and Cash Equivalents
Cash
consists of amounts held in a financial institution and consists of immediately available fund balances. The funds are maintained
at a stable financial institution, generally at amounts in excess of federally insured limits. As of March 31, 2017, and December
31, 2016, approximately $4.6 million and approximately $6.8 million, respectively, in cash and cash equivalents were uninsured.
The Company has not experienced any loss on deposits of cash and cash equivalents to date.
RITTER
PHARMACEUTICALS, INC.
NOTES
TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
Clinical
Trial and Pre-Clinical Study Accruals
The
Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances
known to it at that time. Accrued expenses for pre-clinical studies and clinical trials are based on estimates of costs incurred
and fees that may be associated with services provided by contract research organizations, clinical trial investigational sites,
and other related vendors. Payments under certain contracts with such parties depend on factors such as successful enrollment
of patients, site initiation and the completion of milestones. In accruing service fees, management estimates the time period
over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains
information regarding unbilled services directly from these service providers. However, the Company may be required to estimate
these services based on other information available to it. If the Company underestimates or overestimates the activity or fees
associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary
in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in
estimates may result in a material change in the Company’s accruals.
Recent
Accounting Pronouncements
In
February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2016-02,
Leases
(Topic 842)
(“ASU 2016-02”). The provisions of ASU 2016-02 set out the principles for the recognition, measurement,
presentation and disclosure of leases for both parties to a contract (
i.e.,
lessees and lessors). The new standard requires
lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or
not the lease is effectively a financed purchase by the lessee. This classification will determine whether the lease expense is
recognized based on an effective interest method or on a straight line basis over the term of the lease. A lessee is also required
to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their
classification. Leases with a term of 12 months or less will be accounted for under the existing guidance for operating leases
today. Topic 842 supersedes the previous lease standard, Topic 840
Leases
. The guidance is effective for annual periods
and interim periods within those annual periods beginning after December 15, 2018, and is effective for the Company for the year
ending December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on
the Company’s financial statements.
On
March 30, 2016, the FASB issued Accounting Standards Update No. 2016-09,
Compensation - Stock Compensation (Topic 718): Improvements
to Employee Share-Based Payment Accounting
(“ASU 2016-09”). Among other things, ASU 2016-09 requires that entities
recognize excess tax benefits and deficiencies related to employee share-based payment transactions as income tax expense or benefit.
ASU 2016-09 also eliminates the requirement to reclassify excess tax benefits and deficiencies from operating activities to financing
activities in the statement of cash flows. The guidance is effective for the annual periods and interim periods within those annual
periods beginning after December 15, 2016. The adoption of this standard did not have a material impact on the Company’s
financial statements.
RITTER
PHARMACEUTICALS, INC.
NOTES
TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
On
August 26, 2016, the FASB issued Accounting Standards Update No. 2016-15,
Statement of Cash Flows (Topic 230),
a consensus
of the FASB’s Emerging Issues Task Force (“ASU 2016-15”). The new guidance amends Accounting Standards Codification
No. 230 (“ASC 230”) to add or clarify guidance on the classification of certain cash receipts and payments in the
statement of cash flows. ASC 230 lacks consistent principles for evaluating the classification of cash payments and receipts in
the statement of cash flows. This has led to diversity in practice and, in certain circumstances, financial statement restatements.
Therefore, the FASB issued the ASU 2016-15 with the intent of reducing diversity in practice with respect to eight types of cash
flows. ASU 2016-15 is effective for annual and interim periods in fiscal years beginning after December 15, 2017, and is effective
for the Company for the year ending December 31, 2018. The Company is currently evaluating the impact that the implementation
of this standard will have on the Company’s financial statements.
Other
accounting standards updates effective after March 31, 2017 are not expected to have a material effect on the Company’s
financial statements.
NOTE
4 — PROPERTY AND EQUIPMENT
Property
and equipment consists of the following:
|
|
Estimated
Life
|
|
March
31, 2017
|
|
|
December
31, 2016
|
|
Computer equipment
|
|
5 years
|
|
$
|
10,274
|
|
|
$
|
10,274
|
|
Furniture and fixtures
|
|
7 years
|
|
|
23,325
|
|
|
|
23,325
|
|
Total property and equipment
|
|
|
|
|
33,599
|
|
|
|
33,599
|
|
Accumulated depreciation
|
|
|
|
|
(11,364
|
)
|
|
|
(10,057
|
)
|
Property and equipment, net
|
|
|
|
$
|
22,235
|
|
|
$
|
23,542
|
|
Depreciation
expense of approximately $1,300 was recognized for the three months ended March 31, 2017 and 2016, and classified in general and
administrative expense in the accompanying unaudited condensed statements of operations.
NOTE
5 — COMMITMENTS AND CONTINGENCIES
Master
Services Agreement
On
December 30, 2015, the Company entered into a Master Service Agreement with Covance, Inc. (“Covance”), with an effective
date of December 29, 2015. Pursuant to the terms of the Master Service Agreement, Covance (or one or more of its affiliates) will
provide Phase 1, 2, 3, and 4 clinical services for a clinical study or studies to the Company, and, at the request of the Company,
assist with the design of such studies, in accordance with the terms of separate individual project agreements to be entered into
by the parties. The term of the agreement is for three years and will renew automatically for successive one year periods unless
Covance is no longer providing services under the agreement or either party has terminated the agreement upon written notice.
The Company may terminate the Master Service Agreement or any individual project agreement entered into under the Master Service
Agreement prior to the applicable study’s completion at any time for any reason upon 30 days written notice to Covance,
except when the reason for termination is the safety of subjects, in which case it may be terminated immediately. Covance may
not terminate any individual project agreement without cause, except when the reason for the termination is the safety of subjects,
in which case it may be terminated immediately. In the event of a termination of the Master Service Agreement, Covance will be
entitled to full payment for (i) work performed on the applicable project through the date work on such project is concluded and
(ii) reimbursement for all non-cancellable and non-refundable expenses and financial obligations which Covance (or an affiliate)
has incurred or undertaken on behalf of the Company.
RITTER
PHARMACEUTICALS, INC.
NOTES
TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
Clinical
Supply and Cooperation Agreement with Ricerche Sperimentali Montale (“Ricerche”) and Inalco SpA (“Inalco”)
Effective
July 24, 2015, the Company entered into an amended Clinical Supply and Cooperation Agreement (the “Amended Supply Agreement”)
with Ricerche and Inalco (collectively, “RSM”). The Amended Supply Agreement amends certain terms of the Clinical
Supply and Cooperation Agreement, dated December 16, 2009, amended on September 25, 2010.
Pursuant
to the terms of the Amended Supply Agreement, the Company purchased the exclusive worldwide assignment of all right, title and
interest to a purified GOS product (“Improved GOS”), the composition of matter of the Improved GOS and any information
relating to the Improved GOS, including certain specified technical information and other intellectual property rights (the “Improved
GOS IP”) on July 30, 2015 for $800,000. The Company also issued 100,000 shares of its common stock to RSM pursuant to a
stock purchase agreement. The shares issued to RSM are subject to a lock-up agreement, pursuant to which RSM has agreed that it
will not sell these shares for a period ending on the earlier of (i) the public release by the Company of the final results of
its Phase 2b/3 clinical trial of RP-G28 and (ii) the filing of a Form 10-Q with the SEC for the fiscal quarter in which the Company
receives the results of its Phase 2b/3 clinical trial of RP-G28.
Under
the terms of the Amended Supply Agreement, if the Company fails to make any future option payment to RSM as required under the
terms of the Amended Supply Agreement, the Company may be required to return the Improved GOS IP to RSM. The Amended Supply Agreement
provides that the Company must pay RSM $400,000 within 10 days following FDA approval of a new drug application for the first
product owned or controlled by the Company using Improved GOS as its active pharmaceutical ingredient and to pay RSM the sum of
$250 per kilo for clinical supply of Improved GOS.
Lease
Agreement
The
Company leases office space for its headquarters in California. On July 9, 2015, the Company entered into a lease with Century
Park, a California limited partnership, pursuant to which the Company is leasing approximately 2,780 square feet of office space
in Los Angeles, California for its headquarters. The lease provides for a term of sixty-one (61) months, commencing on October
1, 2015. The Company paid no rent for the first month of the term, paid base rent of $9,174 per month for months 2 through 13
of the term, and will pay base rent of $9,449 per month for months 14 to 25 with increasing base rent for each twelve-month period
thereafter under the term of the lease to a maximum of $10,325 per month for months 50 through 61. The base rent payments do not
include the Company’s proportionate share of any operating expenses, including real estate taxes. The Company has the option
to extend the term of the lease for one five-year term, provided that the rent would be subject to market adjustment at the beginning
of the renewal term.
Rent
expense, which is recognized on a straight-line basis over the lease term, was approximately $38,000 and $29,000 for the three
months ended March 31, 2017 and 2016, respectively, and is recorded in general and administrative expenses in the accompanying
unaudited condensed statements of operations.
RITTER
PHARMACEUTICALS, INC.
NOTES
TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
Legal
The
Company is not currently involved in any legal matters arising in the normal course of business. From time to time, the Company
could become involved in disputes and various litigation matters that arise in the normal course of business. These may include
disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically,
the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential
loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for
the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such
uncertainties, accruals are based on the best information available at the time. As additional information becomes available,
the Company reassesses the potential liability related to pending claims and litigation.
NOTE
6 — STOCKHOLDERS’ EQUITY
Authorized
Shares
On
June 29, 2015, the Company amended and restated its Certificate of Incorporation (“the Amended Certificate”) authorizing
the issuance of 25,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001
par value per share.
As
of March 31, 2017, the Company had 11,619,197 shares of common stock issued and outstanding. Each share of the Company’s
common stock is entitled to one vote, and all shares rank equally as to voting and other matters. There are currently no shares
of preferred stock issued and outstanding. Any preferred stock issued in the future will have the rights, preferences and privileges
that the Company’s Board of Directors may determine from time to time.
2015
Aspire Capital Financing Arrangement
On
December 18, 2015, the Company entered into a common stock purchase agreement (the “2015 Aspire Purchase Agreement”),
with Aspire Capital Fund, LLC, an Illinois limited liability company, (“Aspire Capital”), pursuant to which Aspire
Capital is committed to purchase up to an aggregate of $10.0 million of the Company’s shares of common stock over the approximate
30-month term of the 2015 Aspire Purchase Agreement. In consideration for entering into the 2015 Aspire Purchase Agreement, concurrently
with the execution of the 2015 Aspire Purchase Agreement, the Company issued to Aspire Capital 188,864 shares of the Company’s
common stock as a commitment fee (the “Commitment Shares”). The fair value of the Commitment Shares were capitalized
and recorded as a reduction of additional paid-in capital. Upon execution of the 2015 Aspire Purchase Agreement, the Company sold
500,000 shares of common stock to Aspire Capital at $2.00 per share for proceeds of $1.0 million. The Company sold an additional
888,835 shares of common stock to Aspire Capital on December 8, 2016 at $2.28 per share for approximate proceeds of $2.0 million.
As of March 31, 2017, the Company had issued an aggregate of 1,577,699 shares of its common stock to Aspire Capital for approximate
proceeds of $3.0 million. From March 31, 2017 through May 4, 2017, the Company issued an aggregate of 3,000,000 shares
of its common stock to Aspire Capital for approximate proceeds of $2.0 million.
Any
trading day on which the closing sale price of the Company’s common stock exceeds $0.50, the Company has the right, in its
sole discretion, to present Aspire Capital with a purchase notice, directing Aspire Capital (as principal) to purchase up to 100,000
shares of the Company’s common stock per trading day, for up to $7.0 million of the Company’s common stock in the
aggregate at a per share price, calculated by reference to the prevailing market price of the Company’s common stock (as
provided in the 2015 Aspire Purchase Agreement).
RITTER
PHARMACEUTICALS, INC.
NOTES
TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
Concurrently
with entering into the 2015 Aspire Purchase Agreement, the Company also entered into a registration rights agreement with Aspire
Capital, as amended (the “Registration Agreement”), in which the Company agreed to file one or more registration statements,
as permissible and necessary to register under the Securities Act of 1933, as amended (the “Securities Act”), the
sale of the shares of its common stock that have been and may be issued to Aspire Capital under the 2015 Aspire Purchase Agreement.
On December 31, 2015, the Company filed a registration statement on Form S-1 (File No. 333-208818) pursuant to the terms of the
Registration Agreement, which registration statement was declared effective on February 11, 2016. The Company filed a second registration
statement on Form S-1 (File No. 333-215143), which registration statement was declared effective on February 13, 2017.
On
May 4, 2017, the Company terminated the 2015 Aspire Purchase Agreement and entered into a new common stock purchase agreement
with Aspire Capital (the “2017 Aspire Purchase Agreement”), which provides that upon the terms and conditions set
forth therein (which terms and conditions are substantially similar to those provided in the 2015 Aspire Purchase Agreement),
Aspire Capital is committed to purchase up to an aggregate of $6.5 million of shares of the Company’s common stock over
the 30-month term of the 2017 Aspire Purchase Agreement. As a condition to the 2017 Aspire Purchase Agreement, the Company will
issue 137,324 shares of its common stock to Aspire Capital as a commitment fee (the “2017 Commitment Shares”).
Concurrently with entering into the 2017 Aspire Purchase Agreement, the Company also entered into a registration rights agreement
with Aspire Capital, in which the Company agreed to file one or more registration statements, as permissible and necessary to
register under the Securities Act of 1933, the sale of shares of its common stock that may be issued to Aspire Capital under the
2017 Aspire Purchase Agreement (including the 2017 Commitment Shares”). As of the date of filing this Quarterly Report with
the SEC no shares of common stock have been sold to Aspire Capital under the 2017 Aspire Purchase Agreement.
October
2016 Public Offering
On
October 31, 2016, the Company closed a public offering, selling 2,127,660 shares of the Company’s common stock at a price
to the public of $2.35 per share, for aggregate gross proceeds to the Company of approximately $5.0 million. The Company paid
to the underwriters underwriting discounts and commissions of approximately $0.4 million in connection with the offering, and
approximately $0.2 million of other expenses in connection with the offering.
This
offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-213087), which was declared effective by
the SEC on August 23, 2016. The shelf registration statement allows the Company to issue, from time to time at prices and on terms
to be determined at or prior to the time of an offering, up to $150,000,000 of any combination of an indeterminate number of shares
of common stock, an indeterminate number of shares of preferred stock, an indeterminate principal amount of debt securities, an
indeterminate number of warrants, rights and purchase contracts to purchase common stock or debt securities, and an indeterminate
number of units. If any debt securities are issued at an original issue discount, then the offering price of such debt securities
shall be in such greater principal amount as shall result in an aggregate offering price not to exceed $150,000,000, less the
aggregate dollar amount of all securities previously issued hereunder. The securities registered also include such indeterminate
number of shares of common stock and preferred stock that may be issued upon conversion or exchange of convertible or exchangeable
securities being registered or pursuant to the anti-dilution provisions of any such securities.
NOTE
7 — WARRANTS
Warrants
to purchase an aggregate of 578,323 shares of the Company’s common stock were outstanding at March 31, 2017. These warrants
are all vested and exercisable, have exercise prices ranging from $6.25 to $9.30 per share, with a weighted average exercise price
of $8.45, and expire at various dates through December 2021.
RITTER
PHARMACEUTICALS, INC.
NOTES
TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
NOTE
8 — STOCK-BASED COMPENSATION
Equity
Incentive Plans
The
Company has issued equity awards pursuant to its 2015 Equity Incentive Plan, 2009 Stock Plan and 2008 Stock Plan (collectively
the “Plans”.) The Plans permit the Company to grant non-statutory stock options, incentive stock options and other
equity awards to the Company’s employees, outside directors and consultants; however, incentive stock options may only be
granted to the Company’s employees. Beginning June 29, 2015, no further awards may be granted under the 2009 Stock Plan
or 2008 Stock Plan. As of March 31, 2017, the aggregate number of shares of common stock available for issuance under the 2015
Equity Incentive Plan was 360. However, to the extent awards under the 2008 Plan or 2009 Plan are forfeited or lapse unexercised
or are settled in cash, the common stock subject to such awards will be available for future issuance under the 2015 Equity Incentive
Plan.
The
following represents a summary of the options granted to employees and non-employees that are outstanding at March 31, 2017 and
changes during the period then ended:
|
|
Number
of Shares
|
|
|
Weighted-
Average Exercise Price
|
|
|
Aggregate
Intrinsic Value
|
|
|
Weighted-
Average Remaining Contractual Life (in years)
|
|
Outstanding at December 31, 2016
|
|
|
2,476,924
|
|
|
$
|
6.01
|
|
|
$
|
497,351
|
|
|
|
8.3
|
|
Options granted
|
|
|
88,000
|
|
|
$
|
2.89
|
|
|
|
|
|
|
|
|
|
Options forfeited
|
|
|
―
|
|
|
$
|
―
|
|
|
|
|
|
|
|
|
|
Options exercised
|
|
|
―
|
|
|
$
|
―
|
|
|
|
|
|
|
|
|
|
Outstanding at March 31, 2017
|
|
|
2,564,924
|
|
|
$
|
5.90
|
|
|
$
|
20,110
|
|
|
|
8.1
|
|
Exercisable at March 31, 2017
|
|
|
1,612,603
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
exercise price for an option issued under the Plans is determined by the Board of Directors, but will be (i) in the case of an
incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than
110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair
market value per share on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair
market value per share on the date of grant. The options awarded under the Plans will vest as determined by the Board of Directors
but will not exceed a ten-year period.
Fair
Value of Equity Awards
The
Company utilizes the Black-Scholes option pricing model to value awards under its Plans. Key valuation assumptions include:
|
●
|
Expected
dividend yield.
The expected dividend is assumed to be zero as the Company has never paid dividends and has no current
plans to pay any dividends on the Company’s common stock.
|
|
|
|
|
●
|
Expected
stock-price volatility.
As the Company’s common stock only recently became publicly traded, the expected volatility
is derived from the average historical volatilities of publicly traded companies within the Company’s industry that
the Company considers to be comparable to the Company’s business over a period approximately equal to the expected term.
|
RITTER
PHARMACEUTICALS, INC.
NOTES
TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
|
●
|
Risk-free
interest rate.
The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero
coupon U.S. Treasury notes with maturities approximately equal to the expected term.
|
|
|
|
|
●
|
Expected
term.
The expected term represents the period that the stock-based awards are expected to be outstanding. The Company’s
historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because
of a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by
the SEC. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life
of the options.
|
The
Company elected to adopt the amendments of ASU 2016-09 (described in Note 3) related to the presentation of excess tax benefits
on the statement of cash flows using a prospective transition method but does not expect any impact on its financial statements.
The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:
|
|
Three
months ended March 31,
|
|
|
|
2017
|
|
|
2016
|
|
Expected dividend yield
|
|
|
0.00
|
%
|
|
|
0.00
|
%
|
Expected stock-price volatility
|
|
|
53.90%
- 54.08
|
%
|
|
|
53.53%
- 59.03
|
%
|
Risk-free interest rate
|
|
|
2.31%
- 2.58
|
%
|
|
|
0.18%
- 2.25
|
%
|
Term of options
|
|
|
10
|
|
|
|
10
|
|
Stock price
|
|
|
$1.42
- $3.48
|
|
|
|
$1.07
- $1.79
|
|
Stock-Based
Compensation
The
Company recognized stock-based compensation expense for services within general and administrative expense in the accompanying
statements of operations of approximately $294,000 and $378,000 for the three months ended March 31, 2017 and 2016, respectively.
As of March 31, 2017, there was approximately $1.0 million of total unrecognized compensation cost related to unvested stock-based
compensation arrangements. This cost is expected to be recognized over a weighted average period of 1.3 years.
No
stock options were exercised during the three months ended March 31, 2017. 2,657 options were exercised during the three months
ended March 31, 2016, with approximate proceeds to the Company of $2,000. There was no aggregate intrinsic value of stock options
exercised during the three months ended March 31, 2016.
ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The
following discussion and analysis should be read in conjunction with our interim unaudited condensed financial statements and
related notes included in this Quarterly Report on Form 10-Q (“Quarterly Report”) and the audited financial statements
and notes thereto as of and for the year ended December 31, 2016 and the related Management’s Discussion and Analysis of
Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K filed with the Securities
and Exchange Commission (“SEC”) on February 27, 2017 (“2016 Annual Report”). As used in this report, unless
the context suggests otherwise, “we,” “us,” “our,” or “Ritter” refer to Ritter
Pharmaceuticals, Inc.
Special
Note Regarding Forward-Looking Statements and Industry Data
This
Quarterly Report contains forward-looking statements that involve substantial risks and uncertainties. All statements other than
statements of historical facts contained in this Quarterly Report, including statements regarding our strategy, future operations,
future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth
are forward-looking statements. The words “anticipate,” “believe,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would” and similar expressions
are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results,
performance or achievements to be materially different from any future results, performance or achievements expressed or implied
by the forward-looking statements.
Some
of the factors that we believe could cause actual results to differ from those anticipated or predicted include:
|
●
|
our
ability to obtain additional financing;
|
|
|
|
|
●
|
the
accuracy of our estimates regarding expenses, future revenues and capital requirements;
|
|
|
|
|
●
|
the
success and timing of our preclinical studies and clinical trials;
|
|
|
|
|
●
|
our
ability to obtain and maintain regulatory approval of RP-G28 and any other product candidates we may develop, and the labeling
under any approval we may obtain;
|
|
|
|
|
●
|
regulatory
developments in the United States and other countries;
|
|
|
|
|
●
|
the
performance of third-party manufacturers;
|
|
|
|
|
●
|
our
ability to develop and commercialize our product candidates;
|
|
|
|
|
●
|
our
ability to obtain and maintain intellectual property protection for our product candidates;
|
|
|
|
|
●
|
the
successful development of our sales and marketing capabilities;
|
|
|
|
|
●
|
the
potential markets for our product candidates and our ability to serve those markets;
|
|
|
|
|
●
|
the
rate and degree of market acceptance of our products, if approved;
|
|
|
|
|
●
|
the
success of competing drugs that are or become available; and
|
|
|
|
|
●
|
the
loss of key scientific or management personnel.
|
By
their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics,
and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the
future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each
forward-looking statement contained in this Quarterly Report, we caution you that forward-looking statements are not guarantees
of future performance and that our actual results of operations, financial condition and liquidity, and the development of the
industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report. In
addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we
operate are consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results
or developments in future periods.
Any
forward-looking statement that we make in this Quarterly Report speaks only as of the date of such statement, and we undertake
no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report. You should
also read carefully the factors described in the “Risk Factors” section of this Quarterly Report to better understand
the risks and uncertainties inherent in our business and underlying any forward-looking statements.
This
Quarterly Report includes statistical and other industry and market data that we obtained from industry publications and research,
surveys and studies conducted by third-parties. Industry publications and third-party research, surveys and studies generally
indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy
or completeness of such information. While we believe these industry publications and third-party research, surveys and studies
are reliable, we have not independently verified such data.
Overview
Ritter
Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases.
We are advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality
of prebiotic-based therapeutics into applications intended to have a meaningful impact on a patient’s health. We completed
a Phase 2a clinical trial of our leading product candidate, RP-G28, an orally administered, high purity oligosaccharide at the
end of 2011. We initiated a Phase 2b/3 clinical trial of RP-G28 in March 2016 and completed enrollment in August 2016. In October
2016, the last patient completed dosing and all monitoring visits in our Phase 2b/3 clinical trial of RP-G28 for the treatment
of lactose intolerance. Topline results of the trial were announced in March 2017.
We
have had communications with the FDA regarding our clinical program and regulatory path towards getting RP-G28 adequately studied
and eventually approved. We held a Type C meeting with the FDA in March 2017. We believe that based on the results from its Phase
2b/3 clinical trial, the successful completion of a confirmatory Phase 3 program could be adequate to support a New Drug Application
(NDA) submission and therefore has requested an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The FDA
has granted us an End of Phase 2 meeting, which is expected to occur by the end of 2017.
A
subset of subjects from our Phase 2b/3 clinical trial have been rolled into a 12-month extension study to evaluate long-term durability
of treatment. The study is also evaluating each participant’s microbiome, expanding our knowledge of the effects that RP-G28
may have on adapting the gut microbiota in a beneficial manner. The subjects are expected to complete the 12-month evaluation
during the fourth quarter of 2017.
We
have devoted substantially all of our resources to development efforts relating to RP-G28, including conducting clinical trials
of RP-G28, providing general and administrative support for these operations and protecting our intellectual property. We currently
do not have any products approved for sale and we have not generated any revenue from product sales since our inception. Prior
to our initial public offering in June 2015, we funded our operations primarily through the private placement of preferred stock,
common stock and promissory notes.
We
have incurred net losses in each year since our inception, including net losses of approximately $1.7 million for the three months
ended March 31, 2017. We had an accumulated deficit of approximately $47.1 million as of March 31, 2017. Substantially all of
our net losses resulted from costs incurred in connection with our research and development programs, patent costs, stock-based
compensation, and from general and administrative costs associated with our operations.
Financial
Overview
Revenue
We
have not generated any revenue since our inception. Our ability to generate revenue in the future will depend almost entirely
on our ability to successfully develop, obtain regulatory approval for and then successfully commercialize RP-G28 in the United
States. In the event we choose to pursue a partnering arrangement to commercialize RP-G28 or other products outside the United
States, we would expect to initiate additional research and development and clinical trial activities in the future.
Research
and Development Expenses
Since
our inception, we have focused our resources on our research and development activities, including conducting nonclinical studies
and clinical trials, manufacturing development efforts and activities related to regulatory filings for RP-G28. Our research and
development expenses consist primarily of:
|
●
|
fees
paid to consultants and CROs, including in connection with our nonclinical and clinical trials, and other related clinical
trial fees, such as for investigator grants, patient screening, laboratory work, clinical trial database management, clinical
trial material management and statistical compilation and analysis;
|
|
|
|
|
●
|
costs
related to acquiring and manufacturing clinical trial materials;
|
|
|
|
|
●
|
depreciation
of equipment, computers and furniture and fixtures;
|
|
|
|
|
●
|
costs
related to compliance with regulatory requirements; and
|
|
|
|
|
●
|
overhead
expenses for personnel in research and development functions.
|
From
inception through March 31, 2017, we have incurred approximately $20.2 million in research and development expenses. We plan to
increase our research and development expenses for the foreseeable future as we continue the development of RP-G28 for the reduction
of symptoms associated with lactose intolerance in patients and other indications, subject to the availability of additional funding.
The
successful development of RP-G28 is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs
of the efforts that will be necessary to complete the remainder of the development of RP-G28 or when, if ever, net cash inflows
from RP-G28 may commence. This is due to the numerous risks and uncertainties associated with developing drugs, including the
uncertainty of:
|
●
|
the
scope, rate of progress and expense of our ongoing, as well as any additional, clinical trials and other research and development
activities;
|
|
|
|
|
●
|
future
clinical trial results; and
|
|
|
|
|
●
|
the
timing and receipt of any regulatory approvals.
|
For
example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently
anticipate will be required for the completion of the clinical development of RP-G28 or if we experience significant delays in
enrollment in our clinical trials, we could be required to expend significant additional financial resources and time on the completion
of clinical development.
Patent
Costs
Patent
costs consist primarily of professional fees for legal services to prosecute patents and maintain patent rights.
General
and Administrative Expenses
General
and administrative expenses include allocation of facilities costs, salaries, benefits, and stock-based compensation for employees,
professional fees for directors, fees for independent contractors and accounting and legal services.
We
expect that our general and administrative expenses will increase as we continue to operate as a public company and will increase
further if RP-G28 is approved for commercialization. We believe that these increases will likely include increased costs for director
and officer liability insurance, and increased fees for outside consultants, lawyers and accountants, among other expenses.
Interest
Income
Interest
income consists of interest earned on our cash.
Critical
Accounting Policies and Estimates
This
discussion and analysis is based on our financial statements, which have been prepared in accordance with GAAP. The preparation
of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis,
we evaluate our estimates and judgments, including those related to fair value of financial instruments, research and development
costs, accrued expenses and stock-based compensation. We base our estimates on historical experience, known trends and events
and various other factors we believe to be reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results
may differ from these estimates under different assumptions or conditions. There have been no material changes in our significant
accounting policies as of and for the three months ended March 31, 2017, as compared with the significant accounting policies
described in our Annual Report on Form 10-K for the year ended December 31, 2016.
While
our significant accounting policies are more fully described in Note 3 to the financial statements included in this Quarterly
Report, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating
our financial condition and results of operations.
Fair
Value of Financial Instruments
Fair
value measurement guidelines are prescribed by GAAP to value financial instruments. The guidance includes a definition of fair
value, prescribes methods for measuring fair value, establishes a fair value hierarchy based on the inputs used to measure fair
value and expands disclosures about the use of fair value measurements.
The
valuation techniques utilized are based upon observable and unobservable inputs. Observable inputs reflect market data obtained
from independent sources, while unobservable inputs reflect internal market assumptions. Assets are classified in their entirety
based on the lowest level of input that is significant to the fair value measurement.
These
two types of inputs create the following fair value hierarchy:
Level
1 — Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access
at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such
as exchange-traded instruments and listed equities.
Level
2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly
or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models
consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial
instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or
are supported by observable levels at which transactions are executed in the marketplace.
Level
3 — Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values
are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption
or input is unobservable.
The
carrying amounts reported in the balance sheet for cash and cash equivalents, prepaid expenses, accounts payable and accrued expenses,
approximate the fair values due to the short-term nature of the instruments.
Research
and Development Costs
We
expense the cost of research and development as incurred. Research and development expenses comprise costs incurred in performing
research and development activities, including clinical study costs, contracted services, and other external costs. Nonrefundable
advance payments for goods and services that will be used in future research and development activities are expensed when the
activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730,
Research
and Development
.
Accrued
Expenses
As
part of the process of preparing our financial statements, we are required to estimate our accrued expenses. This process involves
reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service
performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual
cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones
are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and
circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make
adjustments if necessary. The significant estimates in our accrued research and development expenses include fees due to service
providers.
We
base our expenses on our estimates of the services received and efforts expended pursuant to quotes and contracts with our service
providers that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation,
vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors
will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service
fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period.
If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual accordingly.
Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status
and timing of services performed relative to the actual status and timing of services performed may vary and could result in us
reporting amounts that are too high or too low in any particular period.
Stock-based
Compensation
Stock-based
compensation cost for equity awards granted to employees and nonemployees is measured at the grant date based on the calculated
fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line
method, over the requisite service period (generally the vesting period of the equity grant). If we determine that other methods
are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated
for our stock options could change significantly. Higher volatility and longer expected lives would result in an increase to stock-based
compensation expense to non-employees determined at the date of grant.
In
addition to the assumptions used in the Black-Scholes option-pricing model, we also estimate a forfeiture rate to calculate the
stock-based compensation for our equity awards. We will continue to use judgment in evaluating the expected volatility, expected
terms and forfeiture rates utilized for our stock-based compensation calculations on a prospective basis.
Emerging
Growth Company Status
On
April 5, 2012, the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”) was enacted. Section 107 of the JOBS Act
provides that an “emerging growth company” can take advantage of the extended transition period provided in Section
7(a)(2)(B) of the Securities Act of 1933, as amended (the Securities Act), for complying with new or revised accounting standards.
In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies. We have elected to use the extended transition period for complying with new or revised
accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us to delay the adoption of new or revised
accounting standards that have different effective dates for public and private companies until those standards apply to private
companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company
effective dates.
We
are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the
JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely
on certain of these exemptions, including without limitation, (i) providing an auditor’s attestation report on our system
of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any
requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report
providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We
will remain an emerging growth company until the earlier of (i) the last day of the fiscal year (a) following the fifth anniversary
of the date we completed our initial public offering, which was June 29, 2015, (b) in which we have total annual gross revenue
of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our
common stock that is held by non-affiliates exceeded $700.0 million as of the prior June 30th, and (ii) the date on which we have
issued more than $1.0 billion in non-convertible debt during the prior three-year period.
Results
of Operations
Comparison
of the Three Months Ended March 31, 2017 and 2016
The
following table summarizes our results of operations for the three months ended March 31, 2017 and 2016, together with the changes
in those items in dollars and as a percentage:
|
|
For
the Three Months Ended March 31,
|
|
|
Dollar
|
|
|
Percentage
|
|
|
|
2017
|
|
|
2016
|
|
|
Change
|
|
|
Change
|
|
Statement of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating costs
and expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
|
$
|
432,154
|
|
|
$
|
1,882,848
|
|
|
$
|
(1,450,694
|
)
|
|
|
(77
|
%)
|
Patent costs
|
|
|
77,702
|
|
|
|
32,364
|
|
|
|
45,338
|
|
|
|
140
|
%
|
General
and administrative
|
|
|
1,171,325
|
|
|
|
1,235,018
|
|
|
|
(63,693
|
)
|
|
|
(5
|
%)
|
Total operating
costs and expenses
|
|
|
1,681,181
|
|
|
|
3,150,230
|
|
|
|
(1,469,049
|
)
|
|
|
(47
|
%)
|
Loss from operations
|
|
|
(1,681,181
|
)
|
|
|
(3,150,230
|
)
|
|
|
1,469,049
|
|
|
|
47
|
%
|
Other income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
7,946
|
|
|
|
20,566
|
|
|
|
(12,620
|
)
|
|
|
(61
|
%)
|
Other income
|
|
|
―
|
|
|
|
1,214
|
|
|
|
(1,214
|
)
|
|
|
(100
|
%)
|
Total
other income
|
|
|
7,946
|
|
|
|
21,780
|
|
|
|
(13,834
|
)
|
|
|
(64
|
%)
|
Net
loss
|
|
$
|
(1,673,235
|
)
|
|
$
|
(3,128,450
|
)
|
|
$
|
(1,455,215
|
)
|
|
|
47
|
%
|
Research
and Development Expenses
Research
and development expenses decreased by approximately $1.5 million, or 77%, during the three months ended March 31, 2017 as compared
to the three months ended March 31, 2016. The primary reason for this decrease is that our Phase 2b/3 clinical trial, which was
initiated in March 2016, was completed during the fourth quarter of 2016. Research and development expenses during the three months
ended March 31, 2017 primarily reflect extension study costs and continued Phase 2b/3 analysis costs.
Patent
Costs
The
approximate $45,000, or 140%, increase in patent costs during the three months ended March 31, 2017 as compared to the same period
in 2016 was mainly due to certain costs related to our maintenance of patent rights and the prosecution of patents for an increased
number of patents, the new patent applications and our preparation to file national phase applications in certain foreign countries.
During the three months ended March 31, 2017, three new patents were successfully issued.
General
and Administrative Expenses
General
and administrative expenses decreased slightly by approximately $64,000, or 5%, during the three months ended March 31, 2017 as
compared to the three months ended March 31, 2016, primarily due to lower stock-based compensation expense. Approximately $294,000
in stock-based compensation expense was recognized during the three months ended March 31, 2017 as compared to approximately $378,000
during the same period in 2016.
Other
Income
Other
income decreased by approximately $14,000, or 64%, during the three months ended March 31, 2017 as compared to the three months
ended March 31, 2016, due to lower interest income.
Liquidity
and Capital Resources
Since
our inception, we have incurred net losses and negative cash flows from operations and, as of March 31, 2017, we had an accumulated
deficit of approximately $47.1 million. Substantially all of our net losses resulted from costs incurred in connection with our
research and development programs, stock-based compensation, and from general and administrative costs associated with our operations.
At
March 31, 2017, we had working capital of approximately $2.7 million, and cash of approximately $5.1 million. We have not generated
any product revenues and have not achieved profitable operations.
Cash
Flows
The
following table sets forth the significant sources and uses of cash for the periods set forth below:
|
|
For
the Three Months Ended March 31,
|
|
|
|
2017
|
|
|
2016
|
|
Net cash (used in) provided by:
|
|
|
|
|
|
|
|
|
Operating
activities
|
|
$
|
(1,953,973
|
)
|
|
$
|
(1,725,723
|
)
|
Investing activities
|
|
|
—
|
|
|
|
(7,432
|
)
|
Financing activities
|
|
|
—
|
|
|
|
2,130
|
|
Net decrease in cash
|
|
$
|
(1,953,973
|
)
|
|
$
|
(1,731,025
|
)
|
Operating
Activities
Net
cash used in operating activities of approximately $2.0 million during the three months ended March 31, 2017 primarily reflects
our net loss of approximately $1.7 million and a decrease in accounts payable and accrued expenses of approximately $262,000 and
$322,000, respectively, partially offset by stock-based compensation of approximately $294,000.
Net
cash used in operating activities of approximately $1.7 million during the three months March 31, 2016 was mainly due to our net
loss of approximately $3.1 million and an approximate decrease in accrued expenses of $410,000, partially offset by stock-based
compensation of approximately $378,000 and an approximate increase in accounts payable of $1.4 million.
Investing
Activities
Net
cash used in investing activities of approximately $7,000 during the three months ended March 31, 2016 was related to the purchase
of office furniture and equipment.
Financing
Activities
Net
cash provided by financing activities of approximately $2,000 during the three months ended March 31, 2016 represents proceeds
received from the exercise of options for common stock.
Sources
of Liquidity
2015
Aspire Capital Financing Arrangement
On
December 18, 2015, we entered into a common stock purchase agreement (the “2015 Aspire Purchase Agreement”) with Aspire
Capital, LLC, an Illinois limited liability company (“Aspire Capital”) pursuant to which Aspire Capital was committed
to purchase up to an aggregate of $10.0 million of our shares of common stock over the approximately 30-month term of the 2015
Aspire Purchase Agreement. In consideration for entering into the 2015 Aspire Purchase Agreement, concurrently with the execution
of the 2015 Aspire Purchase Agreement, we issued to Aspire Capital 188,864 shares of our common stock as a commitment fee (the
“2015 Commitment Shares”). Upon execution of the 2015 Aspire Purchase Agreement, we sold 500,000 shares of common
stock to Aspire Capital at $2.00 per share for proceeds of $1.0 million. On December 8, 2016, we sold an additional 888,835 shares
of our common stock to Aspire Capital at $2.28 per share for proceeds of $2.0 million. As of March 31, 2017, we had issued an
aggregate of 1,577,699 shares of our common stock to Aspire Capital for aggregate proceeds of approximately $3.0 million. From
March 31, 2017 through May 1, 2017, we sold an aggregate of 3,000,000 shares of our common stock to Aspire Capital for approximate
proceeds of $2.0 million.
The
description of the 2015 Aspire Capital Financing Arrangement set forth in Note 6 of the condensed consolidated financial statements
included in this Quarterly Report is incorporated by reference into Item 2 of this Quarterly Report.
On
May 4, 2017, we terminated the 2015 Aspire Purchase Agreement and entered into a new common stock purchase agreement with Aspire
Capital (the “2017 Aspire Purchase Agreement”), which provides that upon the terms and conditions set forth therein
(which terms and conditions are substantially similar to those provided in the 2015 Aspire Purchase Agreement), Aspire Capital
is committed to purchase up to an aggregate of $6.5 million of shares of our common stock over the 30-month term of the 2017 Aspire
Purchase Agreement. As a condition to the 2017 Aspire Purchase Agreement, we will issue $97,500 in aggregate value of shares of
common stock to Aspire Capital as a commitment fee (the “2017 Commitment Shares”). Concurrently with entering into
the 2017 Aspire Purchase Agreement, we also entered into a registration rights agreement with Aspire Capital, in which we agreed
to file one or more registration statements, as permissible and necessary to register under the Securities Act of 1933, the sale
of shares of our common stock that may be issued to Aspire Capital under the 2017 Aspire Purchase Agreement (including the 2017
Commitment Shares”). As of the date of filing this Quarterly Report with the SEC no shares of common stock have been sold
to Aspire Capital under the 2017 Aspire Purchase Agreement.
We
expect to use the Aspire facility to complement, rather than replace, other financing that may be required during the next twelve
months to continue our operations and support our capital needs.
October
2016 Public Offering
On
October 31, 2016, we closed a public offering of 2,127,660 shares of our common stock at a price to the public of $2.35 per share,
for net proceeds of approximately $4.4 million, after deducting underwriting discounts and commissions and offering expenses payable
by us in the offering. The offering was made pursuant to a shelf registration statement on Form S-3 (Registration Number 333-213087).
Future
Funding Requirements
To
date, we have not generated any revenue. We do not know when, or if, we will generate any revenue from product sales. We do not
expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize
RP-G28 or any of our other product candidates. At the same time, we expect our expenses to increase in connection with our ongoing
development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval
for, our product candidates. Additionally, we have incurred and will continue to incur additional costs associated with operating
as a public company. In addition, subject to obtaining regulatory approval of any of our product candidates, we expect to incur
significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will
need substantial additional funding in connection with our continuing operations.
Based
upon our current operating plan, we believe that our existing cash and cash equivalents, together with interest and any proceeds
received from our sale of shares of common stock to Aspire Capital in the future pursuant to the Aspire Purchase Agreement, will
enable us to fund our operating expenses and capital expenditure requirements through 2017. We intend to devote our existing financial
resources to fund the continued clinical development of RP-G28, including completion of our extension study and Phase 3 program
development activities; to fund expenses associated with the manufacture and product development of RP-G28; to explore potential
orphan indications; and for general corporate purposes, general and administrative expenses, capital expenditures, working capital
and prosecution and maintenance of our intellectual property.
Our
future capital requirements will depend on many factors, including:
|
●
|
the
ability of our product candidates to progress through clinical development successfully;
|
|
|
|
|
●
|
the
outcome, costs and timing of seeking and obtaining FDA;
|
|
|
|
|
●
|
the
willingness of the EMA or other regulatory agencies outside the United States to accept our Phase 2b/3 and any Phase 3 trials
of RP-G28, as well as our other completed and planned clinical and nonclinical studies and other work, as the basis for review
and approval of RP-G28 in the European Union for the reduction of symptoms associated with lactose intolerance in patients;
|
|
|
|
|
●
|
our
need to expand our research and development activities;
|
|
|
|
|
●
|
the
costs associated with securing and establishing commercialization and manufacturing capabilities;
|
|
|
|
|
●
|
market
acceptance of our product candidates;
|
|
|
|
|
●
|
the
costs of acquiring, licensing or investing in businesses, products, product candidates and technologies;
|
|
|
|
|
●
|
our
ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of
any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense
and enforcement of any patents or other intellectual property rights;
|
|
|
|
|
●
|
our
need and ability to hire additional management and scientific and medical personnel;
|
|
|
|
|
●
|
the
effect of competing technological and market developments;
|
|
|
|
|
●
|
our
need to implement additional internal systems and infrastructure, including financial and reporting systems;
|
|
|
|
|
●
|
the
economic and other terms, timing of and success of our existing licensing arrangements and any collaboration, licensing or
other arrangements into which we may enter in the future; and
|
|
|
|
|
●
|
the
costs of operating as a public company.
|
Until
such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination
of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements
and other collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through
the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the
terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders.
Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through
government or other third-party funding, commercialization, marketing and distribution arrangements or other collaborations, strategic
alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future
revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.
Contractual
Obligations and Commitments
There
have been no material changes to our contractual obligations and commitments from those disclosed in our 2016 Annual Report.
Off-Balance
Sheet Arrangements
Through
March 31, 2017, we do not have any off-balance sheet arrangements, as defined by applicable SEC regulations.